1. Home
  2. QURE vs CTKB Comparison

QURE vs CTKB Comparison

Compare QURE & CTKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo uniQure N.V.

QURE

uniQure N.V.

N/A

Current Price

$17.69

Market Cap

663.4M

Sector

Health Care

ML Signal

N/A

Logo Cytek Biosciences Inc.

CTKB

Cytek Biosciences Inc.

N/A

Current Price

$4.13

Market Cap

652.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
QURE
CTKB
Founded
1998
1990
Country
Netherlands
United States
Employees
248
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
663.4M
652.1M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
QURE
CTKB
Price
$17.69
$4.13
Analyst Decision
Buy
Hold
Analyst Count
14
5
Target Price
$45.42
$5.70
AVG Volume (30 Days)
4.5M
652.2K
Earning Date
06-02-2026
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
29.67
N/A
EPS
N/A
N/A
Revenue
$13,107,000.00
$193,015,000.00
Revenue This Year
$126.14
$5.02
Revenue Next Year
$395.00
$7.89
P/E Ratio
N/A
N/A
Revenue Growth
N/A
17.67
52 Week Low
$7.76
$2.37
52 Week High
$71.50
$6.18

Technical Indicators

Market Signals
Indicator
QURE
CTKB
Relative Strength Index (RSI) 46.92 33.97
Support Level $13.29 $4.09
Resistance Level $26.84 $4.26
Average True Range (ATR) 2.09 0.21
MACD 0.11 0.01
Stochastic Oscillator 52.73 16.07

Price Performance

Historical Comparison
QURE
CTKB

About QURE uniQure N.V.

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

About CTKB Cytek Biosciences Inc.

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

Share on Social Networks: